Thread by @VivekSubbiah

📢🥁By popular demand presenting the TOP Oncology publications of 2022.

PS: List not exhaustive - so feel free to tag & add important papers to the list @OncoAlert @NEJM @TheLancetOncol @Annals_Oncology @NatureMedicine @Nature @CD_AACR

First 2022 saw publication of Hallmarks of Cancer: New Dimensions @CD_AACR @AACR @ElizSMcKenna
aacrjournals.org/cancerdiscover…

DESTINY-Changing Results for Advanced Breast Cancer Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer @NEJM @weoncologists @ErikaHamilton9 @teamoncology nejm.org/doi/full/10.10…

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. COMPLETE RESPOSNES in 12/12 patients. Paradigm changing study @NEJM @AndreaCercek @Dr_R_Kurzrock nejm.org/doi/full/10.10…

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation @NEJM nejm.org/doi/full/10.10…

Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO
nature.com/articles/s4158…

DIPG is one of the toughest cancers to treat in children 👉Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma @NEJM @acweyand @medpedshosp nejm.org/doi/full/10.10…

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial @naturemedicine @montypal @NazliDizman
nature.com/articles/s4159…

📢RET emerged as a Tissue agnostic Target in 2022 ! Thanks to @NatureMedicine for taking #tissueagnostic #precisionmedicine to center stage by featuring our paper in the cover image 🎯🧬go.nature.com/3GDj0QF
@OncoAlert

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial @NatureMedicine

nature.com/articles/s4159…

Trial leading to FDA APPRROVAL 👉Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial @TheLancetOncol thelancet.com/journals/lanon…

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
fda.gov/drugs/resource…

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma @NEJM nejm.org/doi/full/10.10…

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma @NEJM nejm.org/doi/full/10.10…

Confirming the DEFINITIVE BENEFIT of Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer. First ever therapy for anaplastic thyroid cancer @Annals_Oncology @myESMO @OncoAlert

annalsofoncology.org/article/S0923-…

FIRST ever positive #targetedtherapy trial in brain tumors 👉Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial @TheLancetOncol thelancet.com/journals/lanon…

#PrecisionMedicine in #pancreaticcancer Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer @NEJM @DavidHongMD @PanCAN nejm.org/doi/full/10.10…

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer @NEJM @FordePatrick nejm.org/doi/full/10.10…

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer @NEJM @StephenVLiu @n8pennell nejm.org/doi/full/10.10…

Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer @ElizSMcKenna @CD_AACR @y_loriot aacrjournals.org/cancerdiscover…

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies @Annals_Oncology annalsofoncology.org/article/S0923-…

AACR Project GENIE: 100,000 Cases and Beyond @AACR @CD_AACR @ElizSMcKenna AACR GENIE is out of the bottle ! aacrjournals.org/cancerdiscover…

In 2023 we look forward to tackle Cancer: slaying the nine-headed Hydra @jacobadashek @Dr_R_Kurzrock @BenWestphalen @Annals_Oncology @myESMO annalsofoncology.org/article/S0923-…

With all this work & more 👉Accelerated approvals hit the target in precision oncology & is just the beginning ! @naturemedicine @GautamMehtaMD @Dr_R_Kurzrock @US_FDA @FDAOncology
nature.com/articles/s4159…

Adding all GU trials list from @DrChoueiri to this list !

https://twitter.com/VivekSubbiah/status/1608833504103759873?s=20&t=71nfZwBQhQOfIAx2WbDNrg

To slay the hydra in The coming decade in precision oncology we need to solve six riddles @damwahida @l_buschhorn @Dr_R_Kurzrock @NatureRevCancer
nature.com/articles/s4156…

@weoncologists

@DrChoueiri

@ErikaHamilton9

@peters_solange

@VivekSubbiah

@jillfeldman4

@marklewismd

@AndresC27622123

@StephenVLiu

@matteolambe

@TiansterZhang

@CathyEngMD

@Icro_Meattini

@YJanjigianMD

@prat_aleix

@ivybelkins

@neerajaiims

This #SoME paper was also published in 2022 👉The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage @ElizSMcKenna @AACR @weoncologists @OncoAlert @neerajaiims @DrChoueiri @JackWestMD @tmprowell @marklewismd @ErikaHamilton9 aacrjournals.org/cancerdiscover…